Replimune gets third chance at US approval for skin cancer drug
- Posted on May 29, 2026
- By Bing News
- 0 Views
- 1 min read
Replimune gets third chance at US approval for skin cancer drug
May 29 (Reuters) - Replimune said on Friday it plans to resubmit the application for its experimental skin cancer drug in the coming days after reaching an agreement with the U.S. FDA, which previously declined to approve the therapy twice. Shares of the company jumped 77% to $8.17 in early trading. The regulator declined to approve vusolimogene oderparepvec, also known as RP1, in April, citing
